Getty Images
October 30, 2023 — -egnite, Inc., a leading cardiovascular digital health company, announced today that novel research on aortic stenosis (AS) was presented by cardiologist Philippe Généreux, MD, Director of the Structural Heart Program of Morristown’s Gagnon Cardiovascular Institute, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
This study, simultaneously published in the Journal of the American College of Cardiology (JACC), leveraged egnite’s de-identified real-world database of over one million patients across 24 teaching and non-teaching United States health systems. Généreux and colleagues sought to unveil treatment patterns and outcomes associated with AS over 4 years.
Key findings demonstrated:
- Patients with AS have substantial untreated mortality risk across all levels of AS severity, but rates of treatment with aortic valve replacement (AVR) remain low (even for patients with severe AS, ~60% were treated within 4 years)
- Moderate AS was almost as deadly as severe AS at 4 years without AVR
“This research is the first of its kind to look at such a large cohort of AS patients over a four-year span. Findings serve as a stark reminder of the poor prognosis associated with untreated AS irrespective of severity, suggesting patients with moderate AS may benefit from intervention,” says Généreux.
This study builds upon a robust body of medical research on the outcomes of patients with AS, highlighting the need for early identification and timely treatment of disease.
For more information: www.egnitehealth.com
November 09, 2023 
